<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194023</url>
  </required_header>
  <id_info>
    <org_study_id>PER-ECL-2011-06-NF</org_study_id>
    <nct_id>NCT02194023</nct_id>
  </id_info>
  <brief_title>Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.</brief_title>
  <official_title>Inhibition of de Novo Plaque Formation and Side Effects of Two New Mouthrinse Formulations: 0.12% and 0.03% Chlorhexidine Digluconate, Respectively, in a 4-day Non-brushing Model. A Triple-blind, Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitat Internacional de Catalunya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dentaid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitat Internacional de Catalunya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current study we tested the hypothesis that new 0.05% Cetylpyridinium chloride (CPC)
      mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX): 1) yield
      similar or better clinical results regarding the inhibition of de novo plaque growth compared
      to those achieved with an already marketed 0.12% CHX mouthrinse (Perio-Aid Treatment without
      alcohol. Dentaid, Spain), 2) reduce the side effects caused by the marketed 0.12% CHX formula
      and 3) that these mouthrinses have no negative microbiological effects, and they control
      total bacterial loads.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with greater reduction of plaque regrowth and side effects.</measure>
    <time_frame>Baseline to 4 days.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Dental Plaque</condition>
  <condition>Side Effects</condition>
  <arm_group>
    <arm_group_label>Placebo (PCB)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo mouthrinse: physiological saline solution (0.9% w/w solution of NaCl in deionized water)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.12%NF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.12% Chlorhexidine digluconate new formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.03%NF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.03% Chlorhexidine digluconate new formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAT (Perio-Aid Treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: PCB</intervention_name>
    <description>Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.</description>
    <arm_group_label>Placebo (PCB)</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.12%NF</intervention_name>
    <description>Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.</description>
    <arm_group_label>0.12%NF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.03%NF</intervention_name>
    <description>Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.</description>
    <arm_group_label>0.03%NF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAT</intervention_name>
    <description>Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.</description>
    <arm_group_label>PAT (Perio-Aid Treatment)</arm_group_label>
    <other_name>Perio-Aid Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-30 years

          -  Good overall health without medical history or medications that could interfere with
             the study conduct.

          -  Minimum of 6 teeth per quadrant.

          -  Absence of probing depths ≥4mm.

        Exclusion Criteria:

          -  Allergy to CHX or to CPC.

          -  Continuous use of CHX or of any other oral antiseptic in the months prior to the
             study.

          -  Any adverse medical background or long-term medications that could affect gingival
             conditions.

          -  Having taken antibiotics in the previous three months.

          -  Moderate to severe gingivitis (bleeding on probing ≥ 40%). 41(Van der Weijden et al.
             1994).

          -  Pregnancy or breastfeeding.

          -  Smokers of more than 5 cigarettes per day.

          -  Orthodontic appliances.

          -  Fixed or removable prostheses.

          -  Systemic diseases that increase the risk for gingival diseases (diabetes mellitus,
             immunosuppression).

          -  Severe dental crowding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Mor-Reinoso</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitat Internacional de Catalunya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UIC dental office, Hospital General de Catalunya</name>
      <address>
        <city>Sant Cugat</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitat Internacional de Catalunya</investigator_affiliation>
    <investigator_full_name>Carolina Mor</investigator_full_name>
    <investigator_title>Master in periodontics by Universitat Internacional de Catalunya.</investigator_title>
  </responsible_party>
  <keyword>chlorhexidine digluconate</keyword>
  <keyword>gingivitis</keyword>
  <keyword>cetylpyridinium chloride</keyword>
  <keyword>mouthrinse</keyword>
  <keyword>dental plaque</keyword>
  <keyword>de novo</keyword>
  <keyword>in vivo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Plaque</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

